Overcoming the Challenges of Low Drug Solubility in the Intravenous Formulation of Solithromycin.

J Pharm Sci

Administration, Cempra Pharmaceuticals Inc., Chapel Hill, North Carolina 27517.

Published: January 2018

Solithromycin is a fluoro-ketolide (a fourth-generation macrolide) antibiotic that has been undergoing clinical trials for the treatment of community-acquired bacterial pneumonia. In this study, development of the tri-amino acid-buffered solithromycin intravenous (IV) formulation was performed to minimize the occurrence of infusion-associated local adverse events (infusion-site pain or phlebitis) observed in patients who received the tartaric acid-buffered IV formulation with a lower buffered capacity during phase I clinical trials. Development of the tri-amino acids-buffered solithromycin IV formulation was achieved using a dynamic in vitro precipitation model. Computational modeling also supports the superiority of the amino acid-buffered formulation over the tartaric aid-buffered formulation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.xphs.2017.10.030DOI Listing

Publication Analysis

Top Keywords

intravenous formulation
8
clinical trials
8
development tri-amino
8
acid-buffered formulation
8
formulation
6
overcoming challenges
4
challenges low
4
low drug
4
drug solubility
4
solubility intravenous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!